electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0433 USD -1.33%
Market Cap: 105.1m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

electroCore, Inc.
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Retained Earnings
-$173.9m
CAGR 3-Years
-13%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Retained Earnings
$2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Retained Earnings
$18.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Retained Earnings
$39.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Retained Earnings
$6.1B
CAGR 3-Years
12%
CAGR 5-Years
23%
CAGR 10-Years
33%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.4m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Retained Earnings?
Retained Earnings
-173.9m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Retained Earnings amounts to -173.9m USD.

What is electroCore, Inc.'s Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-18%

Over the last year, the Retained Earnings growth was -8%. The average annual Retained Earnings growth rates for electroCore, Inc. have been -13% over the past three years , -18% over the past five years .

Back to Top